---
title: "Inaxaplin (VX-147) in APOL1-mediated kidney disease: Dosage"
description: "Formulary evidence on Inaxaplin (VX-147) in APOL1-mediated kidney disease: Dosage. Topics: Phase 3 dose: 45 mg once daily selected by the independent data monitoring committee; Doses compared in the phase 2 portion of AMPLITUDE: 15 mg and 45 mg once daily; AMPLIFIED: 45 mg once daily; Phase 2a regimen: 15 mg once daily for 2 weeks, then 45 mg once daily for 11 weeks; 3 further topics. 7 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description/dosage"
published: "2026-11-15T23:17:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Inaxaplin (VX-147) in APOL1-mediated kidney disease: Dosage

<a id="heading-2.1.2.10.1"></a>

## 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

### Phase 3 dose: 45 mg once daily selected by the independent data monitoring committee

> “An Independent Data Monitoring Committee (IDMC) reviewed blinded and unblinded Phase 2 safety and efficacy data from the Phase 2/3 pivotal trial, which evaluated two different doses of inaxaplin compared to placebo for 12 weeks of treatment in patients ages 18 to 65 years and recommended the selection of a single inaxaplin dose of 45 mg once daily in the Phase 3 portion of the Phase 2/3 study.”

Source: [Vertex Pharmaceuticals press release, phase 3 advancement (2024)](https://news.vrtx.com/news-releases/news-release-details/vertex-advances-inaxaplin-vx-147-phase-3-portion-adaptive-phase)

<a id="topic-2.1.2.10.1-2"></a>

### Doses compared in the phase 2 portion of AMPLITUDE: 15 mg and 45 mg once daily

> “The safety and efficacy of inaxaplin at 15 mg once daily and 45 mg once daily (which is in the lower range of doses explored in these phase 1 studies) is currently being evaluated in a randomized, double-blind, placebo-controlled, phase 2/3 adaptive trial in adults with AMKD (ClinicalTrials.gov number, NCT05312879).”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

> “participants will be randomized to receive 1 of 2 daily doses of IXP or placebo for 12wks.”

Source: [Falk et al. (2022)](https://www.ovid.com/jnls/jasn/fulltext/10.1681/asn.20223311s1181c~design-of-a-phase-23-adaptive-trial-evaluating-inaxaplin-in)

<a id="topic-2.1.2.10.1-3"></a>

### AMPLIFIED: 45 mg once daily

> “In this study, inaxaplin was evaluated as a 45 mg once-daily dose on top of optimized standard of care.”

Source: [Vertex Pharmaceuticals press release, AMPLIFIED results (2026)](https://news.vrtx.com/news-releases/news-release-details/vertex-announces-positive-results-phase-2b-amplified-study)

<a id="topic-2.1.2.10.1-4"></a>

### Phase 2a regimen: 15 mg once daily for 2 weeks, then 45 mg once daily for 11 weeks

> “received inaxaplin treatment for 13 weeks (15 mg once daily for 2 weeks, followed by 45 mg once daily for 11 weeks) (Fig. S2).”

Source: [Egbuna et al. (2023)](https://www.nejm.org/doi/full/10.1056/NEJMoa2202396)

<a id="topic-2.1.2.10.1-5"></a>

### Rationale for the phase 2a doses

> “The administration of once daily doses of 15 mg and 45 mg were selected on the totality of clinical safety, tolerability, and PK from the FIH study (Study 001); as well as toxicology and non-clinical pharmacodynamic (PD) data.”
> “A high dose of 45 mg once daily is selected to maximize the probability of reduction in proteinuria over the 11-week dosing period.”
> “No dose modifications are allowed.”

Source: [Vertex Pharmaceuticals VX19-147-101 protocol (2021)](https://cdn.clinicaltrials.gov/large-docs/62/NCT04340362/Prot_000.pdf)

<a id="topic-2.1.2.10.1-6"></a>

### Doses evaluated in healthy adults

> “Inaxaplin is safe and well tolerated at single doses up to 165 mg and multiple doses up to 120 mg daily for 14 days.”

Source: [Egbuna et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11006409/)

<a id="topic-2.1.2.10.1-7"></a>

### Maximum daily dose, total dose, and treatment duration in the EU trial record

| Field | Quoted record |
| --- | --- |
| Maximum daily dose | “45 mg milligram(s)” |
| Maximum total dose | “4860 mg milligram(s)” |
| Maximum duration of treatment | “108 week(s)” |

Source: [CTIS.eu 2024-515633-15-00](https://ctis.eu/trial/2024-515633-15-00)

## Related pages
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Terms and abbreviations](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/terms-and-abbreviations.md)
- [Inaxaplin (VX-147): APOL1-mediated kidney disease](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/executive-summary.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Product information and disease description](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/product-information-and-disease-description.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Clinical evidence](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/clinical-evidence.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: Economic information and modeling report](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/economics.md)
- [Inaxaplin (VX-147) in APOL1-mediated kidney disease: References](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references) · [Markdown](https://www.evicenter.com/drugs/inaxaplin--apol1-mediated-kidney-disease/references.md)
